Amarin (AMRN) AI Stock Analysis

• Market Cap: $316.13M
• Dividend Yield: N/A
• Average Volume (3M): 91.78K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.53
• Revenue Growth: -6.31%
• EPS Growth: -115.62%
• Country: US
• Employees: 275
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.02
• Shares Outstanding: 20,792,685
• 10 Day Avg. Volume: 103,188
• 30 Day Avg. Volume: 91,775
• PEG Ratio: -1.46
• Price to Book (P/B): 8.20
• Price to Sales (P/S): 17.44
• P/FCF Ratio: -128.50
• Enterprise Value/Market Cap: 0.14
• Enterprise Value/Revenue: 0.20
• Enterprise Value/Gross Profit: 0.50
• Enterprise Value/Ebitda: -0.85
• 1Y Price Target: $10.00
• Price Target Upside: -50.62% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: $17.00 ▼(-16.05% Downside)

Amarin's overall stock score reflects a challenging financial position with ongoing losses and cash flow issues. The positive momentum in the U.S. market and strategic cost reductions are encouraging, but valuation concerns and mixed technical indicators weigh on the score. The earnings call provided a more optimistic outlook, but significant risks remain.

Positive Factors

Revenue Growth

The 17% revenue growth indicates strong market demand and effective sales strategies, particularly in the U.S., supporting long-term business expansion.

Strategic Partnerships

The partnership with Recordati enhances market penetration in Europe, leveraging local expertise and infrastructure, which can drive sustainable growth.

FDA Labeling Update

The FDA update may shift clinical practices towards VASCEPA, enhancing its competitive position and driving long-term demand in cardiovascular treatment.

Negative Factors

Declining Rest of World Revenue

The decline in Rest of World revenue highlights challenges in international markets, which could hinder global expansion efforts and revenue diversification.

Ongoing Restructuring Costs

High restructuring costs impact profitability and cash flow, potentially delaying financial recovery and limiting investment in growth initiatives.

Negative Cash Flow

Persistent negative cash flow indicates operational inefficiencies and financial strain, which can challenge long-term sustainability and growth investment.

Amarin Business Overview & Revenue Model

Company Description

Amarin Corporation plc is a biopharmaceutical company focused on developing and commercializing innovative therapeutics to improve cardiovascular health. The company is primarily known for its flagship product, Vascepa (icosapent ethyl), an omega-3 fatty acid approved for use in reducing cardiovascular risk in patients with high triglyceride levels. Amarin operates within the pharmaceutical sector, specifically in the cardiovascular disease treatment market, and is committed to advancing scientific research and development to address unmet medical needs.

How the Company Makes Money

Amarin generates revenue primarily through the sale of its flagship product, Vascepa, which is marketed to healthcare providers and patients for the treatment of cardiovascular conditions. The company earns income from prescription sales in various markets, including the United States, where it has established a robust distribution network. Additionally, Amarin may enter into partnerships or collaborations with other pharmaceutical companies to develop or commercialize new products, which can provide additional revenue streams. The company also benefits from patent protections and exclusivity periods for its products, allowing it to capture a significant share of the market before facing generic competition. Overall, its revenue model relies heavily on the successful promotion and sale of its approved therapeutics, alongside potential future product developments and collaborations.

Amarin Financial Statement Overview

Summary

Amarin faces significant financial challenges with consistent net losses and negative cash flow from operations. Despite slight improvements in revenue growth and free cash flow, operational inefficiencies and profitability issues remain. The low leverage provides some stability, but the negative return on equity and ongoing losses are concerning.

Income Statement

Amarin's income statement shows a challenging financial position with declining revenue over the past few years, although there is a slight revenue growth in the TTM period. The gross profit margin has decreased from its peak in 2021, indicating reduced efficiency in generating profit from sales. The company has been consistently operating at a net loss, with negative EBIT and EBITDA margins, highlighting ongoing operational challenges.

Balance Sheet

The balance sheet reflects a relatively stable financial structure with a low debt-to-equity ratio, suggesting limited leverage and potential for financial stability. However, the negative return on equity indicates that the company is not generating positive returns for shareholders. The equity ratio remains strong, indicating a solid capital base relative to total assets.

Cash Flow

Cash flow analysis shows improvement in free cash flow growth in the TTM period, but the company continues to experience negative operating cash flow. The free cash flow to net income ratio is slightly above 1, indicating that free cash flow is covering net losses, but the operating cash flow to net income ratio remains negative, pointing to ongoing cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	225.62M	228.61M	306.91M	369.19M	583.19M	614.06M
Gross Profit	88.13M	81.38M	165.54M	242.48M	461.86M	482.62M
EBITDA	-52.20M	-74.18M	-50.70M	-100.69M	14.28M	-12.71M
Net Income	-86.19M	-82.18M	-59.11M	-105.80M	7.73M	-18.00M
Balance Sheet
Total Assets	659.81M	685.35M	831.68M	886.18M	1.07B	966.02M
Cash, Cash Equivalents and Short-Term Investments	286.59M	294.22M	320.66M	309.36M	454.13M	500.93M
Total Debt	6.73M	7.72M	8.74M	10.02M	8.58M	9.15M
Total Liabilities	200.92M	199.17M	279.59M	290.85M	400.97M	338.52M
Stockholders Equity	458.89M	486.18M	552.10M	595.33M	667.10M	627.50M
Cash Flow
Free Cash Flow	-21.86M	-31.02M	6.88M	-179.98M	-66.53M	-22.00M
Operating Cash Flow	-21.86M	-31.03M	6.91M	-179.98M	-66.53M	-21.75M
Investing Cash Flow	-10.58M	-45.98M	-25.62M	175.18M	104.09M	-376.96M
Financing Cash Flow	-2.00M	-1.44M	230.89K	-378.77K	-5.07M	-58.91M

Amarin Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 20.25
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMRN, the sentiment is Positive. The current price of 20.25 is above the 20-day moving average (MA) of 16.16, above the 50-day MA of 17.32, and above the 200-day MA of 13.86, indicating a neutral trend. The MACD of -0.23 indicates Negative momentum. The RSI at 51.23 is Neutral, neither overbought nor oversold. The STOCH value of 73.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AMRN.

Amarin Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RIGL	83 Outperform	$887.96M	7.93	220.06%	―	79.13%	2798.12%
ALT	55 Neutral	$546.75M	―	-52.61%	―	-61.54%	31.25%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AMRN	50 Neutral	$316.13M	-3.65	-17.35%	―	-6.31%	-115.62%
CRVS	41 Neutral	$657.95M	―	-35.82%	―	―	79.27%
RCKT	40 Underperform	$359.30M	―	-74.88%	―	―	18.39%
ALDX	37 Underperform	$282.77M	―	-64.31%	―	―	4.23%

Amarin Corporate Events

Amarin Appoints David Keenan as COO

David Keenan, Ph.D., has been appointed as the Executive Vice President and Chief Operating Officer of Amarin Corporation, effective October 17, 2025. Dr. Keenan, who joined Amarin in May 2022, brings over 30 years of leadership experience in the biopharmaceutical and medical device industries, with expertise in operations, quality management, and international M&A.